12 Aug rxrx stock Insights: Graph, Statistics, and Tools
Surprising fact: more than 13 million shares traded in a single session tells you how closely people watch this biotech right now.
I track recursion pharmaceuticals from live feeds and exchange snapshots. Today the price sits in a tight day’s range near $5, which hints at decent liquidity but unclear momentum.
I cross-check Nasdaq, eToro, and Robinhood data to keep the picture honest. The company’s 52-week range (3.79–12.36) gives me a quick risk gauge when I look at price movements.
Quick read: this piece blends platform-level science and daily market behavior. I flag hard results like EPS and volume, and I separate evidence from my interpretation.
Key Takeaways
- Volume and day’s range show active trading but mixed momentum.
- I reconcile multiple sources to reduce data lag and bias.
- recursion’s platform links biology and technology—pipeline matters here.
- Negative EPS is typical for clinical-stage biotech; treat it as context.
- Salt Lake City headquarters matters for talent and partnerships.
rxrx stock market snapshot and performance statistics (present)
This snapshot pulls the latest price action and key metrics for recursion pharmaceuticals so you can see where the market sits today.
Live graph overview: the intraday range is tight at $5.20–$5.54, while the 52-week channel spans $3.79–$12.36. Trading near $5.29 today places the name in the lower third of that range, which frames mean-reversion odds versus downside risk.
Key trading stats (today)
- Price (eToro): $5.29 — 24h -1.31%
- Volume reads: 13.24M (Nasdaq) — Robinhood reports 18.67M
- Avg volume range: 20.20M–28.08M (below-average participation)
- Bid / Ask snapshot: 5.35 x100 / 5.43 x700 — tight spread
Valuation and trend at a glance
| Metric | Value | Context |
|---|---|---|
| Market cap | $2.30–$2.33B | Nasdaq & Robinhood consensus |
| EV / Revenue | ~29.30 | Reflects limited sales vs R&D assets |
| P/S • P/B | 29.89 • 2.53 | Typical for a clinical-stage pharmaceuticals company |
| Performance | Week -3.99% • Year -15.77% | Beta 0.92; 1y target est $6.50 |
Quick evidence note: I triangulate prices from eToro, fundamentals from Nasdaq-style feeds, and volume context from Robinhood to reduce single-source error. That habit keeps intraday decisions grounded.
Recursion Pharmaceuticals fundamentals: business model, pipeline, and partnerships
I start with the platform because it shapes everything that follows. Recursion is a platform-first biotech that stitches automation, AI/ML, and in vivo validation into one loop. That combination is where biology and software meet and why the discovery tempo matters.
Pipeline drives value. REC-994 (Phase 2) targets cerebral cavernous malformation; REC-2282 sits in Phase 2/3 for neurofibromatosis type 2. REC-4881 runs Phase 1b/2 for familial adenomatous polyposis and Phase 2 in AXIN1/APC mutant cancers. REC-3964 is Phase 1 for C. difficile, while RBM39 is preclinical for HR-proficient ovarian cancer.
Partnerships add credibility. Bayer, Roche & Genentech, and Takeda — plus academic links like the University of Utah Research Foundation and Ohio State Innovation Foundation — signal external validation of the approach.
“Platform claims are only meaningful when they produce faster hit-to-lead cycles and clear clinical results.”
On finances: revenue is $64.6M with EPS -1.81 and net income -649.13M. Cash sits at $525.11M and levered free cash flow is -186.02M. ROA -39.08% and ROE -86.34% reflect growth-stage dynamics, not a mature income story.
- Why I watch cash: runway and financing strategy matter given negative earnings.
- Why partnerships matter: they reduce single-lab risk and speed validation.
Tools and guide to analyze rxrx stock today
When I open market tools, I use a short checklist to avoid noise and focus on what matters for recursion pharmaceuticals.
Tools I use
- Nasdaq Advanced Chart — structure and delayed market data.
- eToro — quick price pulse and change metrics for today.
- Robinhood — average volume, intraday high/low, and trade color.
- Analyst dashboards — consensus, ratings, and 1y targets.
Quick step-by-step
- Mark the 52-week bounds (3.79–12.36) and VWAP; then spot local support.
- Compare live volume to the 20.20M–28.08M average; ignore thin breakouts.
- Read valuation via EV (~1.89B), P/S (~29.89), and cash runway — not P/E.
| Focus | Tool | Key read |
|---|---|---|
| Price context | Nasdaq Chart | 52-week bounds, VWAP, pivots |
| Liquidity | Robinhood | Avg vol 20.20M, intraday 5.20–5.54 |
| Pulse | eToro | Live-like price $5.29; day/week/year moves |
| Consensus | Analyst dashboards | 1y target $6.50; ratings mix |
“I triangulate feeds: when two of three sources line up on price and range, I log the move and update my thesis.”
Predictions: base case aligns with the $6.50 target; upside if pipeline or partnerships surprise; downside if trial delays or funding needs appear. For background on analyst expectations see analyst expectations.
Conclusion
My bottom line: recursion pharmaceuticals combines a credible platform with multiple drug programs, but near-term potential hinges on trial timing and financing. Market signals — price near $5.29, mixed volume, and valuation — reflect that tradeoff.
I expect a base-case around the $6.50 one-year target if milestones proceed and markets stay neutral. Upside needs strong clinical results or a large partnership. Downside comes from delays, dilution, or weak earnings reports.
Quick FAQ:
Is it profitable? No — negative EPS and income are normal for this stage.
What moves the share? Clinical readouts, partner news, and capital raises.
Where is the company based? Salt Lake City — a meaningful hub for talent and collaborations.
Evidence: see price, cash ≈ $525M, revenue and pipeline data above. I watch cash burn and catalyst dates closely. Verify claims across Nasdaq, eToro, and Robinhood before acting.
FAQ
What does the live graph for Recursion Pharmaceuticals tell me today?
How should I interpret today’s trading stats and volume numbers?
What valuation metrics matter for a clinical-stage biotech like Recursion?
FAQ
What does the live graph for Recursion Pharmaceuticals tell me today?
The intraday chart shows price action within the day’s range of .20–.54, while the 52-week view puts recent moves in context of longer-term volatility. Look for volume spikes around major news; they confirm conviction. I watch moving averages and relative volume to separate noise from real momentum.
How should I interpret today’s trading stats and volume numbers?
Today’s reported volume sits between 13.24M and 18.67M, below the typical average band of about 20.20M–28.08M. Lower-than-average trade often means fewer participants, so price swings can be exaggerated. Pair volume with price direction: rising price on rising volume is healthier than the opposite.
What valuation metrics matter for a clinical-stage biotech like Recursion?
For early-stage drug developers, market cap, price-to-sales, price-to-book, and enterprise value give a surface view. But more telling are cash runway and burn. With an estimated market cap near .3B, P/S ≈ 29.9, P/B ≈ 2.53 and EV around
FAQ
What does the live graph for Recursion Pharmaceuticals tell me today?
The intraday chart shows price action within the day’s range of $5.20–$5.54, while the 52-week view puts recent moves in context of longer-term volatility. Look for volume spikes around major news; they confirm conviction. I watch moving averages and relative volume to separate noise from real momentum.
How should I interpret today’s trading stats and volume numbers?
Today’s reported volume sits between 13.24M and 18.67M, below the typical average band of about 20.20M–28.08M. Lower-than-average trade often means fewer participants, so price swings can be exaggerated. Pair volume with price direction: rising price on rising volume is healthier than the opposite.
What valuation metrics matter for a clinical-stage biotech like Recursion?
For early-stage drug developers, market cap, price-to-sales, price-to-book, and enterprise value give a surface view. But more telling are cash runway and burn. With an estimated market cap near $2.3B, P/S ≈ 29.9, P/B ≈ 2.53 and EV around $1.89B, you need to weigh lofty multiples against pipeline milestones.
How healthy is the company’s balance sheet and cash position?
The latest figures show cash of roughly $525M, which supports operations while the company advances trials. Negative FCF (about -$186M) and negative EPS reflect R&D spending typical for clinical-stage firms. I track runway and upcoming financing risks closely.
What are the most important drugs in the pipeline to watch?
Key clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, plus preclinical programs like RBM39. Milestone readouts, trial starts, or partnerships tied to these assets are the main catalysts that move sentiment and valuation.
How do analysts frame the one-year price target?
The consensus one-year target sits near $6.50 as a base case. That assumes successful trial progression and operational execution. Upside requires clear clinical wins or strategic partnerships; downside comes from negative data or funding shortfalls.
Which platforms and tools should I use to analyze this biotechnology name?
I use advanced charting on Nasdaq, real-time brokers like Robinhood or eToro for quick fills, and analyst dashboards for consensus estimates. Combine technicals, fundamentals, and news feeds to form a complete view.
How do I read volatility and beta for a biotech stock?
Beta near 0.92 suggests stock moves slightly less than the market on average, but biotech-specific volatility still dominates around trial news. Implied volatility from options and observed intraday range help gauge short-term risk.
What are practical steps to read the company’s chart and volume correctly?
Start with price vs. moving averages, add volume bars, then check relative strength over 1 week to 1 year. Identify support and resistance, note gaps near news dates, and use volume to confirm breakout or false move. Keep position size small around binary events.
How should I interpret profitability metrics like ROA and ROE for this firm?
Negative ROA (~-39%) and ROE (~-86%) stem from operating losses and heavy R&D investment. For clinical-stage biotech, these are common and less informative than runway, funding plans, and milestone timelines.
How can I triangulate data across Nasdaq, Robinhood, and eToro for accuracy?
Cross-check price, volume, and corporate actions across platforms. Use official filings (SEC) for authoritative figures. Minor timing differences are normal; large discrepancies usually point to feed errors or delayed updates.
What scenarios should I prepare for if I hold shares going into a trial readout?
Plan three scenarios: base (trial meets primary endpoints, price moves toward the ~$6.50 target), upside (surprising efficacy or partner deals pushing valuation higher), and downside (failed readout or funding need triggering steep declines). Set stop-losses and size positions to risk only what you can tolerate.
Are partnerships and collaborations significant catalysts here?
Yes. Partnerships can de-risk programs, bring upfront cash, and validate the AI-first discovery platform. Announcements often trigger re-ratings, so watch press releases and SEC filings closely.
.89B, you need to weigh lofty multiples against pipeline milestones.
How healthy is the company’s balance sheet and cash position?
The latest figures show cash of roughly 5M, which supports operations while the company advances trials. Negative FCF (about -6M) and negative EPS reflect R&D spending typical for clinical-stage firms. I track runway and upcoming financing risks closely.
What are the most important drugs in the pipeline to watch?
Key clinical programs include REC-994, REC-2282, REC-4881, and REC-3964, plus preclinical programs like RBM39. Milestone readouts, trial starts, or partnerships tied to these assets are the main catalysts that move sentiment and valuation.
How do analysts frame the one-year price target?
The consensus one-year target sits near .50 as a base case. That assumes successful trial progression and operational execution. Upside requires clear clinical wins or strategic partnerships; downside comes from negative data or funding shortfalls.
Which platforms and tools should I use to analyze this biotechnology name?
I use advanced charting on Nasdaq, real-time brokers like Robinhood or eToro for quick fills, and analyst dashboards for consensus estimates. Combine technicals, fundamentals, and news feeds to form a complete view.
How do I read volatility and beta for a biotech stock?
Beta near 0.92 suggests stock moves slightly less than the market on average, but biotech-specific volatility still dominates around trial news. Implied volatility from options and observed intraday range help gauge short-term risk.
What are practical steps to read the company’s chart and volume correctly?
Start with price vs. moving averages, add volume bars, then check relative strength over 1 week to 1 year. Identify support and resistance, note gaps near news dates, and use volume to confirm breakout or false move. Keep position size small around binary events.
How should I interpret profitability metrics like ROA and ROE for this firm?
Negative ROA (~-39%) and ROE (~-86%) stem from operating losses and heavy R&D investment. For clinical-stage biotech, these are common and less informative than runway, funding plans, and milestone timelines.
How can I triangulate data across Nasdaq, Robinhood, and eToro for accuracy?
Cross-check price, volume, and corporate actions across platforms. Use official filings (SEC) for authoritative figures. Minor timing differences are normal; large discrepancies usually point to feed errors or delayed updates.
What scenarios should I prepare for if I hold shares going into a trial readout?
Plan three scenarios: base (trial meets primary endpoints, price moves toward the ~.50 target), upside (surprising efficacy or partner deals pushing valuation higher), and downside (failed readout or funding need triggering steep declines). Set stop-losses and size positions to risk only what you can tolerate.
Are partnerships and collaborations significant catalysts here?
Yes. Partnerships can de-risk programs, bring upfront cash, and validate the AI-first discovery platform. Announcements often trigger re-ratings, so watch press releases and SEC filings closely.